Three HER-2-activating mechanisms have been found in NSCLC: mutation (occurring in 1–4% of cases), amplification ( occurring in 2–5% of cases) and overexpression (occurring in 10–15% of cases)109. Here, ERBB2 is linked to non-small cell lung carcinoma.